化疗导致的心脏毒性生物标志物研究进展  

Research progress of biomarkers of cardiotoxicity induced by chemotherapy

作　　者：王鑫 李晓琪 迟伟群(综述)[1] 刘禹(审校)[1] WANG Xin;LI Xiaoqi;CHI Weiqun;LIU Yu(Department of Clinical Laboratory,the Fourth Affiliated Hospital of HarbinMedical University,Harbin,Heilongjiang 150001,China)

机构地区：[1]哈尔滨医科大学附属第四医院检验科,黑龙江哈尔滨150001

出　　处：《国际检验医学杂志》2022年第16期2037-2042,共6页International Journal of Laboratory Medicine

基　　金：黑龙江省自然科学基金面上项目(H2017025);中国博士后科学基金特别资助项目(2018T110318)。

摘　　要：随着肿瘤患者治疗生存率的提高,以肿瘤治疗相关心脏功能不全(CTRCD)为主的心脏毒性已成为威胁患者生存的严重问题。与心脏活检、超声心动图等检查方式相比,生物标志物具有及时性和检测简便的优点。应用生物标志物在早期发现化疗导致的心脏毒性,并及时改善治疗方案,可有效减少或避免心脏损伤的发生。本文对在化疗引起的心肌细胞早期损伤、炎性反应及心脏功能性改变等毒性反应中表达异常的传统生物标志物、新型生物标志物和潜在生物标志物在心脏毒性方面的应用及研究现状进行综述,以期及时发现心脏毒性,为提高患者生存质量提供指导。With the improvement of patients′survival rate of tumor treatment,cardiotoxicity of cancer treatment-related cardiac dysfunction(CTRCD)has become a serious problem threatening the survival of patients.Compared with cardiac biopsy,echocardiography and other examination methods,biomarkers have the advantages of timeliness and simple detection.The application of biomarkers in early detection of chemotherapy-induced cardiotoxicity and timely improvement of treatment plan can effectively reduce or avoid the occurrence of cardiac injury.In this paper,we reviewed the traditional biomarkers,new biomarkers and potential biomarkers with abnormal expression in chemotherapy-induced cardiomyocyte early damage,inflammatory response and cardiac functional changes as well as the application and research status of cardiotoxicity markers in judging the cardiotoxicity of chemotherapy,so as to provide guidance for timely detection of cardiotoxicity and improve the patients′quality of life.

关 键 词：化疗 心脏毒性 生物标志物 肿瘤 心脏功能不全 

分 类 号：R737.9[医药卫生—肿瘤]